|
Antidepressant Update
|
|
|
|
|
|
 |
|
The antidepressant sertraline may reduce the risk of recurrent
depression and increase the period of time between episodes of
depression in people with diabetes, according to a study supported by
grants from the National Institutes of Health and Pfizer, Inc. Earlier
studies have shown that about 15 percent of people with diabetes who
suffer from recurrent depression do not respond to antidepression
treatment. Patrick J. Lustman, M.D., of the Washington University
School of Medicine in St. Louis, followed 152 people with diabetes who
recovered from depression while taking sertraline. He tracked them for
up to one year, or until their depression set in again–at which time they
were put back on the drug. Participants taking sertraline were
significantly less likely to have a recurrence of depression. After one
year, 65.8 percent of those taking sertraline remained depression free,
while 47.9 percent of those taking a placebo were without depression.
|
|
|
|
|
|